Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.67 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 11/20 | 0.43 |
| ▸ | CA1 | P00915 | 11/20 | 0.43 |
| ▸ | CA2 | P00918 | 11/20 | 0.43 |
| ▸ | CA7 | P43166 | 11/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 11/20 | 0.43 |
| ▸ | CA6 | P23280 | 10/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA3 | P07451 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA5A | P35218 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939796 | 0.88 | MMP2 (0.61) | MMP2IMPDH2CA12CA1CA2 | |
| SCHEMBL939794 | 0.88 | MMP2 (0.70) | MMP2IMPDH2CA12CA1CA2 | |
| SCHEMBL940311 | 0.88 | MMP2 (0.73) | MMP2IMPDH2CA12CA1CA2 | |
| SCHEMBL941261 | 0.85 | MMP2 (0.80) | MMP2IMPDH2CA12CA1CA2 | |
| SCHEMBL940425 | 0.84 | MMP2 (0.67) | MMP2IMPDH2CA12CA1CA2 | |
| SCHEMBL940447 | 0.82 | MMP2 (0.56) | MMP2CA12CA1CA2CA7 | |
| SCHEMBL939510 | 0.82 | MMP2 (0.60) | MMP2IMPDH2CA12CA1CA2 | |
| SCHEMBL940093 | 0.81 | MMP2 (0.74) | MMP2IMPDH2CA1CA2TDO2 | |
| SCHEMBL940056 | 0.81 | MMP2 (0.80) | MMP2IMPDH2CA1CA2TDO2 | |
| SCHEMBL940427 | 0.80 | MMP2 (1.00) | MMP2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2268612-B1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| CN-102036953-A | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | MMP2 18/4885IMPDH2 1704/4885CA12 700/4885 |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | MMP2 18/4885IMPDH2 1704/4885CA12 700/4885 |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | MMP2 19/4885IMPDH2 1807/4885CA12 686/4885 |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | MMP2 19/4885IMPDH2 1807/4885CA12 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.